Vasculitis & polymyalgia rheumatica
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis
Authors' conclusion
In patients with EGPA, treatment for 2 years with anti-IL-5/R therapies is associated with durable rates of remission, discontinuation of OGCs, bEOS depletion, and low relapse rates. Switching from mepolizumab to benralizumab enhances bEOS depletion and OGC sparing.
Study context
- Population
- Patients with eosinophilic granulomatosis with polyangiitis (EGPA) who entered the open-label extension (OLE) of the MANDARA trialentered the OLE
- Participants
- 128 patients
- Comparison
- Continued benralizumab vs switch from mepolizumab to benralizumab
- Benralizumab/benralizumabn = 66
- Mepolizumab/benralizumabn = 62
- Primary endpoint
- Remission (BVAS = 0 and oral GC dose ≤4 mg/d)
- Follow-up
- Week 104
Methodological detailspreceding 52-week double-blind randomised period (1:1)
- Preceding 52-week double-blind randomised period (1:1)
Primary result
As reported in the abstract
Remission
Further findings
Withdrawn from oral GC · weeks 49 to 52
Withdrawn from oral GC · weeks 101 to 104
Cumulative oral GC dose · OLE year 1
| Outcome | Benralizumab/benralizumab | Mepolizumab/benralizumab |
|---|---|---|
| No relapses · OLE year 1 | 77.3% | — not stated in the abstract |
| Blood eosinophil count | median 20 cells/µL | — not stated in the abstract |
— not stated in the abstract
- Blood eosinophil count: benralizumab/benralizumab value at weeks 52 and 100
Blood eosinophil count
- Mepolizumab/benralizumab: median decreased from 70 cells/µL to 20 cells/µL 4 weeks after switching
Safety
Adverse events
Serious adverse events
Original publication
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. Published 7 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →